Deloitte Digital’s Post

Personalized medicine is changing the game. Amazing insights from Badrinath Sambamurthi and Rajesh Singh on how technology and cross functional teams need to come together to meet patients and providers where they are to continue to deliver these life changing therapies. ICYMI this morning - recap below! #personalizedmedicine #cellandgenetherapy #DF24

In three decades, cell therapies have transformed from science fiction to clinical reality. Can they now be advanced to become standard of care? #ISCT2024 confirmed the momentum carried by cell therapies, tackling unmet medical needs in cancer, genetic diseases, autoimmunity, and neurological disorders. Experiences gained with approved CAR-T therapies continue to to reveal that benefits clearly outweigh risks, as an #FDA speaker confirmed. In the meantime, promising results are hinting at potential new cures for currently intractable diseases. The cell therapy community’s ambition to tackle toughest challenges is higher than ever: At #ISCT2024, scientists, doctors, entrepreneurs, and investors presented their relentless efforts to advance process technologies, automation, data collection and AI-guided optimization, while striving to enable point-of-care or even bed-side manufacturing. But what struck us the most during these five days in Vancouver is a clear shift in mindset: Appreciating the hard-learned lessons that potent cells can turn useless when processed inadequately, most new therapy and technology developments are now targeted towards maximizing cell quality before cell quantity. We are extremely grateful for the inspiring and energizing discussions and are looking forward to seeing great progress in the field until the next edition of the ISCT, International Society for Cell & Gene Therapy conference! #ISCT2024 #Astraveus #Lakhesys #CGTmanufacturing #CellTherapy #Bioprocessing #Biotech

“The science is advancing faster than ever before, but now we need to ensure our healthcare systems can keep up.” – Tim Hunt, CEO of ARM That was one conclusion from the October Bridging the Gap webinar. Other key points included: ✳️ Patient Access: Many eligible patients still face barriers to receiving life-saving therapies like CAR T-cell treatment. ✳️ Cost Considerations: While upfront costs are high, these therapies can offer long-term savings by reducing years of ongoing treatments. ✳️ Regulatory Challenges: The current healthcare infrastructure is struggling to adapt to the rapid pace of innovation in gene and cell therapy. ✳️ Global Perspective: Healthcare systems worldwide must collaborate to make these therapies accessible to more patients. Read the full recap here: https://hubs.ly/Q030nF_T0 #CellAndGeneTherapy #HealthcareInnovation #BridgingTheGap

Advanced therapies like CAR-T, gene therapies, and tissue-engineered treatments hold immense promise—but delivering these therapies to patients is a challenge as complex as developing them. From navigating immune responses and precise targeting to ensuring scalability and accessibility, delivery plays a pivotal role in turning scientific breakthroughs into life-changing treatments. In this video, TTP’s Device Innovation Lead, Matthew Parker, and Head of Advanced Therapies, Stuart Lowe, dive into the intricate world of advanced therapy delivery, exploring: ✅ Why delivery strategies vary for cells, genes, and tissues ✅ How encapsulation and targeted delivery are reshaping patient outcomes ✅ The cross-disciplinary innovation needed to overcome transport, storage, and cost barriers Watch the full video as they share insights into cracking the code of drug delivery for advanced therapies. Watch the full video: https://lnkd.in/e_G6m5mE #AdvancedTherapies #DrugDelivery #CellAndGeneTherapy #MedTech

Manufacturing is a real and very present bottleneck for advanced therapies. But as technologies evolve, and we target a broader range of indications, the associated delivery challenges are being brought to the fore. It was a pleasure to talk to TTP plc's Head of Advanced Therapies Stuart Lowe about emerging modalities, and the innovations that are needed to deliver these at scale.

This year’s ESACT was a great snapshot of a rapidly evolving cell and gene therapy (CGT) industry. Our experts Andrea Vervoort, Keara Sutherland, and Oliver Varette highlight 3 standout conference insights: ✔ The need for viral vectors is expected to continue to grow. This necessitates efficient and economical manufacturing methods to meet rising demand while also being mindful of environmental footprints. ✔ Industry leveraging AI/ML to model and optimize manufacturing processes, predict optimal outcomes and improve efficiency. Marinna Madrid, presented an AI/ML model for the automated production of stem cells for personalized regenerative cell therapies. There is also an emphasis on curating datasets and minimizing data silos within organizations. ✔ An excellent talk by Cath Green highlighted the benefits of providing robust biomanufacturing capabilities to academics. This enables important research to reach clinical trials, which is crucial for scenarios such as pandemics. Integrating industry and academia is pivotal for accelerating innovative therapies. Ultimately, CGT manufacturing is undeniably complex, and industry and academia collaboration is the cornerstone for the CGT sector to take transformative strides. #biomanufacturing #ESACT2024 #innovation

It's happening. ATW 2025 starts next week. Here's what to expect. The future of cell and gene therapy will take center stage as industry leaders gather to discuss the groundbreaking innovations that are shaping the field. From the latest in CRISPR-based gene therapy and CAR-T innovations to emerging trends in non-oncology indications like autoimmune diseases and cardiovascular conditions, we are going to explore how these therapies are revolutionizing medicine. Key topics include: ➡️ Cutting-edge gene-editing technologies and their clinical applications. ➡️ Addressing challenges in scalability, cost-effectiveness, and manufacturing. ➡️ Expanding therapeutic horizons beyond oncology into rare diseases and chronic conditions. ➡️ Collaboration between regulatory agencies and developers to streamline approvals. Join us as we dive into the transformative technologies ushering in the next generation of medicine. Stay tuned for updates from Dallas! #ATW25 #Biotech

🌟 Excited to be at Advanced Therapies Week by Phacilitate in Dallas this week! 🌟 As the cell and gene therapy field continues its rapid evolution, challenges like access, scalability, and infrastructure are more critical than ever. At BBG Advanced Therapies, we’re innovating new ways to help you meet these challenges and I’m thrilled to present a new way we can work together to bring life-saving treatments closer to patients in rural and underserved areas. Recent news from the industry highlights just how pressing these issues are: 🔍 The FDA's new guidance on CAR-T development (December 2024) recommends considerations for cell collection and logistics to support reducing vein-to-vein time. 🔗 https://lnkd.in/gKydeAKQ 🔍 The CIBMTR (Center for International Blood & Marrow Transplant Research) highlights the ongoing barriers to access for rural patients. 🔗 https://lnkd.in/gxCVDaPB. 💡 These updates reinforce why innovations for patient access are so important. By eliminating the need for patients to travel long distances, we’re expanding access to therapies, reducing logistical burdens, and ensuring that no patient is left behind. If you’re attending #ATW2025, come visit me in the Innovation Zone or connect with me to discuss how we can work together to make advanced therapes accessible. 👉 What’s the biggest barrier you see to scaling advanced therapies in 2025? Let me know in the comments! #AdvancedTherapies #Innovation #PatientAccess #CellAndGeneTherapy #ATW2025

Day 8 of 12 of #CSGmas - Todays topic - 2025 Trends 📈 In a previous post I asked what people are seeing in trends wise moving into 2025 and have had some great conversations regarding this. From my perspective and speaking to candidates the areas I am seeing growth in are: 1) Precision Medicine: AI and biomarker-driven approaches are accelerating the development of highly targeted therapies. 2) Complex Clinical Trials: Next-gen therapies bring unique challenges, making specialised clinical talent more critical than ever. 3) Cell & Gene Therapies: these therapies are growing within oncology pipelines, raising the bar for funding, execution, and expertise. 4) Global Talent Competition: The race to secure top-tier talent who can take therapies from theory to fruition is becoming more and more competitive. The opportunities are vast, but success depends on having the right people to deliver. If this sounds like something you are seeing moving into the new year or wanting to discuss further let’s connect and discuss. #oncologytrends #2025 #12daysofcsgmas